Akebia Therapeutics, Inc. 8-K

What Happened
Akebia Therapeutics (AKBA) filed an 8‑K reporting two material actions: (1) it signed a lease on January 27, 2026 to relocate its corporate headquarters to 180 Third Avenue, Waltham, MA, and (2) on January 28, 2026 it amended executive severance agreements for CEO John P. Butler and CFO Erik J. Ostrowski to align severance terms with market practices. The new premises total ~43,474 sq ft (28,518 sq ft office + 14,956 sq ft lab). The company expects to occupy the office space around September 1, 2026 and the lab space around November 1, 2026.

Key Details

• Lease: 43,474 sq ft at 180 Third Avenue, Waltham, MA; initial term is 84 months (7 years) beginning on the office term commencement date; one five‑year extension option.
• Rent & costs:
  • Office annual rent starts at $898,317 and increases by $1.00 per sq ft each successive rent year during the initial term.
  • Lab annual rent starts at $1,046,920 and escalates ~3.0% each successive rent year during the initial term.
  • Security deposit: $810,515 in the form of an irrevocable letter of credit.
  • Tenant pays taxes, insurance, maintenance and other operating expenses; landlord will perform and pay for specified initial build‑out work.
• Financial obligation: The lease creates a direct, long‑term financial commitment for the company (rent and related operating expenses).
• Severance (effective Jan 28, 2026):
  • CEO John P. Butler — If terminated without Cause or resigns for Good Reason (not following a change in control): 12 months base salary continuation, lump sum = 100% of annual target bonus, up to 12 months COBRA premium reimbursement, and continued vesting of unvested equity during the severance period. If termination occurs within 12 months after a Change in Control: 24 months salary continuation, lump sum = 200% of annual target bonus, up to 24 months COBRA reimbursement, and accelerated vesting (100% for awards granted on/before the effective date; post‑effective‑date awards vest if termination occurs within 12 months post‑CIC). Payments conditioned on executing a release and complying with restrictive covenants (including non‑competition/disparagement for one year post‑termination).
  • CFO Erik J. Ostrowski — If terminated without Cause or resigns for Good Reason (not following a change in control): 12 months base salary continuation, up to 12 months COBRA reimbursement, and continued vesting of unvested equity during the severance period. If termination occurs within 12 months after a Change in Control: 12 months salary continuation, lump sum = 100% of annual target bonus, up to 12 months COBRA reimbursement, and accelerated vesting (100% for awards granted on/before the effective date; post‑effective‑date awards vest if termination occurs within 12 months post‑CIC). Similar release and covenant conditions apply.

Why It Matters

• Lease: The new Waltham lease commits Akebia to a multi‑year occupancy with defined rent escalators and an $810k letter‑of‑credit security — this increases the company’s fixed operating obligations and will affect future cash flow and occupancy costs compared with its current Cambridge lease (which expires Sept 11, 2026). Landlord-paid build‑out limits near‑term cash outlays by the company.
• Severance: Updated severance terms formalize potential cash and equity obligations on executive terminations and are notably more generous in a change‑in‑control scenario (especially for the CEO). These provisions can increase contingent liabilities in certain events but are conditioned on a release and compliance with post‑employment covenants.